Bristol Myers’ Cancer Therapy Win Strengthens its Oncology Pipeline

insidermonkey.com · 2026-09-11

Bristol-Myers Squibb Company (NYSE:BMY) said its experimental CAR-T cell therapy, arlocabtagene autoleucel (arlo-cel), met the main goal of a mid-stage trial in patients with advanced multiple myeloma...

Read the full story at insidermonkey.com →